Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
62 participants
INTERVENTIONAL
2004-05-31
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.
NCT00584532
Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer
NCT01325311
Genistein in Treating Patients With Prostate Cancer
NCT01126879
Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy
NCT00058266
Nutrition and Prostate Cancer
NCT03532308
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Genistein Combined Polysaccharide (GCP)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
No treatment (surgery \[RRP\], radiation, or hormones) prior to study entry.
The patient has decided, after consultation with his own doctor, to have no treatment intervention (surgery \[RRP\], radiation, or hormones) for the next six months.
PSA between 2.0 and 10.0 ng/ml.
If PSA is \>10.0, patient must have been on Active Surveillance for 12 months prior to study initiation.
No known allergy to soy or soy products.
The patient is not currently taking more than 2 grams of genistein a day in nutritional or diet enhancing supplements (OTC supplements).
\-
Exclusion Criteria
Allergy to soy or soy products
Prior history of treatment for prostate cancer.
\-
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Davis
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of California, Davis
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Hackman, PhD
Role: PRINCIPAL_INVESTIGATOR
University of California, Davis
Ralph W deVere White, MD
Role: STUDY_DIRECTOR
University of California, Davis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Davis
Sacramento, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y, Sun B. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology. 2004 Feb;63(2):259-63. doi: 10.1016/j.urology.2003.09.061.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
200412146
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.